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In England, aortic aneurysms account for more
than 11,000 admissions per year, and unusually for a
vascular disorder, the prevalence of this condition
appears to be increasing.1 Abdominal aneurysms and
their management remain a significant health prob-
lem that is likely to assume greater importance with
the expansion of the elderly population. At present,
there is a general surgical consensus that patients who
have abdominal aneurysms in excess of 5.5 cm
should be recommended for elective surgical repair,
which has a mortality rate approaching 5%.2,3 At pre-
sent it is uncertain whether patients with aneurysms
between 4 and 5.5 cm should undergo surgery, and
this is the subject of a prospective randomized trial
that is expected to be reported in 1998.4
Current management strategies for small (<5.5
cm) aneurysms involve serial ultrasound examina-
tion, with elective surgery when growth exceeds 1
cm per year or the absolute aneurysm size reaches
5.5 cm.5 Small aortic aneurysms expand exponen-
tially by approximately 10% of their diameter per
year,6,7 although this rate may be significantly high-
er in patients who are hypertensive or who smoke.8
Collin9 monitored 145 patients with screen-detect-
ed aneurysms <4 cm and demonstrated that 14%
required elective surgery as a result of rapid expan-
sion or growth to a diameter exceeding 5.5 cm. In
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addition to the complications of elective surgical
repair, patients with small aneurysms also have a
finite risk of rupture. Cronenwett et al.10 demon-
strated that 9% of patients with small AAAs required
emergency surgery during a 3-year study, whereas
Katz et al.11 demonstrated an annual rupture rate of
3.3% for patients with aneurysms <5 cm. With the
advent of community-based or hospital-based
screening programs, the number of small aneurysms
presenting to vascular surgeons is likely to increase.
Clearly, a therapeutic strategy is required to limit
both the expansion and rupture rate of small
abdominal aneurysms and to offer an effective treat-
ment to patients with this condition.
Consequent to this requirement, the biochemi-
cal and molecular mechanisms of aneurysm forma-
tion have begun to attract more attention, and these
studies have suggested novel therapeutic avenues.
The characteristic feature of early abdominal
aneurysms is the segmental depletion of elastin. The
loss of elastin from the arterial wall has been related
to a generalized enhancement of systemic and local-
ized proteolytic capacity; increased levels of neu-
trophil elastase12 and tissue matrix metalloproteinas-
es (MMPs)13 have been reported in patients who
have AAAs. The MMPs are a family of zinc-depen-
dent enzymes that have the capability to degrade all
components of the extracellular matrix. These
enzymes are secreted by mesenchymal cells of the
arterial wall and infiltrating white cells. The enzymes
are divided on the basis of their substrate specificity
into the collagenases (MMP-1), the gelatinases
(MMP-2 and MMP-9), and the stromelysins
(MMP-3).14 Recent evidence has suggested that ele-
vated levels of MMPs may be the crucial determi-
nant of aneurysm formation and growth, as all mem-
bers of the elastolytic and collagenolytic MMPs are
demonstrable in aneurysm tissue at elevated lev-
els.15-22
These enzymes therefore provide a potential tar-
get for pharmacologic therapy aimed at preventing
aortic wall matrix degradation and aneurysm
growth. The aim of this study was to investigate the
use of doxycycline, a nonspecific MMP inhibitor, in
a previously described organ culture model of
aneurysmal disease.23 The model used porcine aor-
tic segments that were cultured in sterile conditions.
The segments were exposed to a brief pulse of
exogenous elastase to initiate matrix degradation
and endogenous MMP production. The arterial
organ culture model facilitated the study of isolated
cellular interactions and allowed the investigation of
various doses of doxycycline within the system.
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METHODS
Organ culture. Porcine thoracic aortas were
kindly provided by Dawkins International Ltd.
(Nuneaton, U.K.). Thoracic as opposed to abdomi-
nal aortas were used, as numerous sections were
obtained from each aorta and this proved easier
using thoracic tissue. Porcine thoracic aorta has a
predictable structure containing numerous elastic
lamellae.24 Under sterile conditions, fat and loose
adventitial tissue were removed. One square cen-
timeter segments of aorta were excised and pinned,
intimal surface uppermost, onto a polyester gauze
support resting on sylgard resin (Dow Corning,
Seneffe, Belgium) in the base of a 6 cm Petri dish
(Fisons Loughborough, U.K.). Samples were
denuded of endothelium and cultured for 14 days in
standard medium (7 ml) containing 5% fetal calf
serum (Sera Lab, Crawley, U.K.), which was
changed after 24 hours and then every 48
hours.23,24
Experimental design. Porcine thoracic aortas
were divided into six sections. One sample was har-
vested fresh. One was cultured for 14 days without
exposure to elastase or doxycycline. Four samples
were preincubated in culture medium supplement-
ed with porcine pancreatic elastase (100 units/ml;
Calbiochem, Nottingham, U.K.) for 24 hours.
After this period, one sample was harvested and the
three remaining aortic sections were washed thor-
oughly to remove all traces of exogenous elastase
and cultured for a further 13 days in standard cul-
ture medium or culture medium supplemented by
two concentrations of doxycycline (1 mg/L and 10
mg/L). The experiment was replicated in eight
separate aortas.
Exposure to a brief pulse of elastase was neces-
sary in this experimental design because previous
studies had demonstrated that incubation with elas-
tase for 24 hours initiated a time-dependent elastin
degradation and MMP production in aortic organ
cultures, even though exogenous elastase was not
detectable by casin zymography at 3 days. Interest-
ingly, culture of aortic tissue in standard conditions
was associated with MMP induction, but did not
result in elastin degradation in the absence of exoge-
nous elastase.23
Histologic analysis. After fixation in formalin,
samples were dehydrated in 99% industrial methylat-
ed spirit (Sigma, Poole, U.K.), transferred into
xylene (Sigma) for 4 hours, and embedded in paraf-
fin wax. Sections (4 m m) were stained with both
hematoxylin and eosin and Miller’s elastin and van
Gieson’s stain,25 which gave a good balance in stain-
ing for elastin (black), collagen (pink), and smooth
muscle cells (yellow).
Stereologic tissue analysis. The volume frac-
tions of elastin, collagen, and smooth muscle cells in
the extracellular matrix were determined by stereo-
logic analysis as described previously.26,27 Aortic sec-
tions, stained with Miller’s elastin and van Gieson’s
stain, were viewed at 400· magnification using an
Olympus microscope incorporating an eyepiece
graticule with a 100-point test grid (Graticules Ltd.,
Kent, U.K.). One hundred test points were then
analyzed, with test points hitting black indicating
elastin, points hitting yellow indicating smooth mus-
cle cells, and points hitting pink indicating collagen.
After analysis, the relative volume fraction of each
component was calculated. To maintain a constant
frame of reference throughout all experiments, the
adventitial aspect of the media was point counted,
with eight randomly chosen fields quantified for
each sample. Stereologic tissue analysis reflects the
ability of the tissue to take up histologic stain, and
thus measures of collagen, elastin, and smooth mus-
cle cells reflect changes in the relative concentrations
of each of these elements rather than changes in pro-
tein content. This form of tissue analysis will there-
fore demonstrate an inverse relationship between
collagen and elastin in the extracellular matrix. Pre-
vious experiments have determined the interobserv-
er limits of agreement for this technique in our insti-
tution.23
Gel enzymography. Metalloproteinases were
extracted from frozen tissue using the method of
Vine and Powell15 as previously described.23 Tissue
was thawed over ice, diced into 1 mm3 pieces, and
homogenized in buffer. The homogenate was cen-
trifuged and dialyzed, and the protein concentration
was standardized for each sample to 0.9 mg/ml with
phosphate-buffered saline solution.
Substrate gels were prepared by incorporating
gelatin (1 mg/ml; Sigma) into a 10% SDS-polyacry-
lamide gel. Fifteen microliters of standardized tissue
extract plus an equal volume of nonreducing sample
buffer were loaded onto the gel. Electrophoresis was
performed at 60 mA for 4 hours at 4° C with the
Mini-Protean II system (Bio-Rad, Hemel Hempsted,
U.K.), after which the gel was washed three times
with 2.5% Triton X-100 (Sigma), incubated in
buffer for 18 hours, and finally stained with
Coomassie blue R250. The molecular weight of
each band was estimated by comparison with the
positions of known molecular weight standards
(Bio-Rad). The relative density of each lytic band
was determined from negative photographic images
of gels with a Pharmacia LKB Imagemaster scanning
densitometer (Pharmacia LKB, St. Albans, Hert-
fordshire) and expressed as a product of the optical
density and area of the band. The protein concen-
tration used in this analysis had been previously
determined to be within the linear range for densit-
ometric quantification (data not shown). To allow
for variation between zymographic gels, all paired
samples were run on the same gel, and paired statis-
tics were used in analysis. No comparison was made
between different gels.
Immunoblotting. Tissue extracts were fraction-
ated on a 10% SDS-polyacrylamide and transferred
to a nitrocellulose membrane (Hybond ECL, Amer-
sham, U.K.) in the Mini-transblott apparatus (Bio-
Rad) as previously described.23 Mouse monoclonal
antibodies specific for MMP-2, MMP-9, and the tis-
sue inhibitors of metalloproteinases TIMP-1 and
TIMP-2 (Oncogene Science, Paris) were used to
identify MMPs and TIMPs within the samples.
These antihuman antibodies had been demonstrated
to cross-react with porcine proteins in a prior
study.23
Statistical analysis. Median values and
interquartile ranges for the volume fractions of
elastin, collagen, and smooth muscle cells were cal-
culated for all sections. These were then compared
using nonpaired, nonparametric analysis (Mann-
Whitney U test). The densitometric analysis of
MMPs were compared using the nonparametric,
paired, one-tailed Wilcoxon test.
RESULTS
Stereologic analysis. The histologic appear-
ance of four paired aortic segments are illustrated
in Fig. 1. There was no reduction in the elastin
concentration in the sections of aorta cultured in
standard conditions for 14 days. Exposure to a 24
hour pulse of elastase-induced (100 u/ml) matrix
degradation in a time-dependent manner as
described previously,23 resulting in significant
elastin depletion at 14 days.
Stereologic analysis confirmed that there was a
significant preservation of elastin in the elastase-
exposed aortic sections cultured in standard medium
supplemented by doxycycline (10 mg/L), when
compared with the sections not treated with doxy-
cycline (p < 0.001; W = 28.0, 95% confidence inter-
val, 36.00 to 9.9). There was also a trend to elastin
preservation in the sections treated with a dose of 1
mg/L, although this was not significant (p = 0.09;
W = 39.0; 95% confidence interval, 12.5 to –0.62).
The percentage elastin concentration for all aortic
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Fig. 1. Four histologic sections from the same aorta stained with Miller’s elastin and van
Gieson’s stain (original magnification, 400· ). Cultured control (A) and three sections exposed
to a pulse of elastase, one subsequently cultured in standard medium (B), one in standard
medium supplemented by doxycycline 1 mg/L (C), and one in standard medium supple-
mented by doxycycline 10 mg/L (D). Adventitial collagen (D) is noted to be particularly well
preserved, although the significance of this is unknown.
A
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segments is illustrated in Fig. 2. The reduction in
elastin concentration after exposure to elastase was
accompanied by a parallel increase in collagen con-
centration, which obviously reflects the type of stere-
ologic volume fraction analysis used. 
Gelatinolytic activity. Gelatin enzymography
confirmed a time-dependent increase in MMP activ-
ity within elastase-treated cultures compared with
the control samples. Fresh aortic tissue demonstrat-
ed lytic bands at 70 kd, whereas elastase-treated
samples demonstrated a progressive increase in
gelatinolytic activity at 70 kd (doublet) and appear-
ance of proteolytic bands at 90 kd and 250 kd.
Immunoblotting with specific monoclonal anti-
bodies demonstrated immunoreactivity of a 70 kd
doublet with MMP-2 antibody and a 90 and 250 kd
protein reacting with an antibody to MMP-9 (data
not shown).
A representative zymogram of four paired aortic
sections is depicted in Fig. 3. Densitometric analysis
of the aortic segments treated with doxycycline
demonstrated that these samples had significantly
less MMP-9 activity when compared with those cul-
tured in standard medium after elastase exposure (p
= 0.04, W = 33.0; and p = 0.02, W = 35.0 for doxy-
cycline concentrations of 1 mg/L and 10 mg/L,
respectively). MMP-9 activity as a percentage of the
cultured control is illustrated in Fig. 4. The reduc-
tion in MMP-9 activity was accompanied by a lesser
reduction in MMP-2 activity, although this was not
significant (p = 0.45, WI = 9.0; and p = 0.08, WI =
25.0 for doxycycline concentrations of 1 mg/L and
10 mg/L, respectively).
Immunoblotting for the endogenous MMP
inhibitors, the tissue inhibitors of metalloproteinases
(TIMP-1 and TIMP-2), demonstrated no obvious
difference in activity in the doxycycline-treated seg-
ments (Fig. 5).
DISCUSSION
The management of small aneurysms is current-
ly one of the critical problems in vascular surgery,
and it is clearly desirable that pharmacologic treat-
ments are developed to retard the expansion rate of
such aneurysms. Previous experimental studies have
suggested that b -blockers may inhibit aneurysm
growth by lowering blood pressure and promoting
collagen and elastin cross-linkage.28-30 Interest in
these agents was further stimulated by a report from
Gadowski et al.,31 who demonstrated that the
expansion rate of large aneurysms was lower in a
cohort of patients who took b -blockers. Unfortu-
nately, this was an uncontrolled, nonrandomized
study, and recent data from the MRC small
aneurysm study has suggested that b -blockade has
no effect of aneurysm growth.32 Although the role
of b -blockers in aneurysms is defined by a random-
Fig. 2. Graph plots percentage elastin concentration
(median values and Q3) for fresh aorta (Fresh), cultured
control (CC), elastase exposed after 24 hours (E1), elas-
tase exposed after 14 days (E14), doxycycline-treated 1
mg/L (D1), and doxycycline-treated 10 mg/L (D10).
Fig. 3. Gelatin zymogram shows metalloproteinase activ-
ity for all sections of one aorta and demonstrates reduction
in MMP-9 activity in doxycycline-treated segments. Posi-
tive C, HT 1080 fibrosarcoma cell line, which produces
large quantities of MMP-2 and MMP-9. Fresh, Freshly
harvested, noncultured aortic sample. Cultured C, Aorta
cultured without exposure to elastase for 14 days. Elastase,
Aorta exposed to elastase for 24 hours and then cultured
in standard conditions for a further 13 days. Doxy 1 mg/l
and Doxy 10 mg/l, Aortas exposed to elastase for 24 hours
and then cultured with doxycycline for 13 days.
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ized trial,33 the necessity for alternative strategies has
suggested that potential therapeutic agents should
be specifically targeted to pathophysiologic process-
es within the aneurysm wall.
Many of the features observed during aneurysm
development and expansion may be related to an
overproduction of MMPs within the arterial wall.
Particularly important in this respect are the gelati-
nolytic enzymes MMP-2 and MMP-9. Recently,
Freestone et al.34 investigated the enzyme profile in
aneurysms of differing diameters and demonstrated
that the elastolytic MMP-2 was the dominant MMP
in small aneurysms, whereas MMP-9 was preferen-
tially elevated in larger vessels. This investigation
suggested that MMP-2 might play a role in
aneurysm genesis, whereas MMP-9 may be more
important in expansion of larger aneurysms. Sakali-
hasan et al.35 confirmed these observations by
describing high levels of activated MMP-9 in
aneurysmal tissue, whereas Newman et al.36 have
previously localized MMP-9 activity to the mononu-
clear infiltrate in the aneurysm wall.
An etiologic role in aneurysm genesis for the
elastolytic MMPs, and MMP-2 in particular, has
been suggested by two contemporary studies that
demonstrated that smooth muscle cells cultured
from the abdominal aneurysm wall expressed higher
levels of MMP-2 than cells from control tissue cul-
ture.37,38 These results suggested that a primary
elastolytic insult from high levels of MMP-2 may ini-
tiate aneurysm formation and growth. Clearly, these
findings require extensive further investigation into
the control of MMP-2 production, as traditionally
MMP-2 is considered as a relatively nonresponsive
gene with different promoters to the majority of the
MMP family.14
Theoretically, elastin degradation will release
elastin-derived peptides, which further stimulate
MMP production and induce leukocyte infiltration
into the tissue.12,39 These changes may then initiate
a cascade leading to elastin degradation, leukocyte
infiltration, and aneurysm formation. Recent in vitro
investigations from our department have confirmed
that an initial wave of elastin degradation may
induce aneurysmal type changes in arterial tis-
sue,23,40 and these sequelae have also been observed
in the elastase-infusion animal model of aneurysmal
disease.41-43 Evidence from the above studies has
suggested that the elastolytic MMP-2 and MMP-9
may be intimately involved in aneurysm pathogene-
sis and growth, and these enzymes provide an attrac-
tive target for pharmacologic agents aimed at reduc-
ing small aneurysm expansion and rupture.
One agent that may fulfill the criteria for use in
small aneurysms is doxycycline. Doxycycline belongs
to the family of tetracyclines and chemically modified
tetracyclines. These groups of antibiotics have proven
long-term safety and efficacy in the treatment of acne
vulgaris. The drugs are frequently used in relatively
low doses for many months or years and have good
side-effect profiles.44-46 Doxycycline nonselectively
inhibits MMPs by binding to the active zinc sites47
and also by binding to an inactive calcium site, which
causes conformational change48 and loss of enzymat-
ic activity. Secondary mechanisms of inhibition have
also been proposed, which include a reduction in
activation,49 decreased gene expression,50 and stabi-
lization of specific and nonspecific inhibition.51
Fig. 4. Graph plots MMP-9 activity (median values and
Q3) as a fraction of cultured control (CC), confirming
that elastase exposure induced MMP-9 activity (E) that
was progressively inhibited by an increasing dose of doxy-
cycline at 1 mg/L and 10 mg/L (D1 and D10).
Fig. 5. Immunoblot demonstrates TIMP-1 immunoreac-
tivity. Cultured C, Aorta cultured without exposure to
elastase for 14 days. Elastase, Aorta exposed to elastase for
24 hours and then cultured in standard conditions for a
further 13 days. Doxy 1 mg/l and Doxy 10 mg/l, Aortas
exposed to elastase for 24 hours and then cultured with
doxycycline for 13 days. Positive C, HT 1080 fibrosarco-
ma cell line, which produces large quantities of MMP-2
and MMP-9.
The present study has shown that doxycycline
significantly reduces elastin degradation and MMP-
9 activity in an in vitro model of aneurysmal disease
and also has an insignificant effect to reduce the pro-
duction of MMP-2. The findings from our in vitro
study are similar to those from Petrinec et al.,50 who
investigated the therapeutic potential of doxycycline
in the elastase infusion rodent model. The authors
observed preservation of aortic medial elastin with
doxycycline administration and suggested that this
was as a result of reduced MMP-9 production by the
infiltrating inflammatory cells. We have not looked
specifically at the role of leukocyte infiltration in the
present study, although it would be possible to
incorporate a macrophage-rich infiltrate into this
model.23
Doxycycline provides a potentially attractive
pharmacotherapeutic agent for the long-term treat-
ment of patients who have small AAAs, with the aim
of inhibiting or reducing aneurysm growth rate. The
doses of doxycycline used in the present study are
achievable with oral administration. A loading dose
of 200 mg followed by 100 mg/day gives a serum
level of 3.5 mg/L, with a tissue/serum concentra-
tion of greater than one.52 The therapeutic potential
of this family of drugs in aneurysmal disease deserves
further consideration.
We thank Pfizer Limited (Sandwich, Kent, U.K.) for
kindly donating the doxycycline used in this project, and
Dawkins International Ltd. for provision of tissue samples.
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